A new tool to observe cell behavior has revealed surprising clues about how cancer cells respond to therapy - and may offer a way to further refine personalized cancer treatments. The approach, developed by investigators at Vanderbilt-Ingram Cancer Center, shows that erlotinib - a targeted therapy that acts on a growth factor receptor mutated in some lung, brain and other cancers - doesn't simply kill tumor cells as was previously assumed. The drug also causes some tumor cells to go into a non-dividing (quiescent) state or to slow down their rate of division...
via Health News from Medical News Today Read More Here..
No comments:
Post a Comment